Table 1.
Isotype analysis of anti-S and anti-RBD IgG antibodies in immunized mice.
| Timepoints analyzed | IgG2c and IgG1 titers and Ratio IgG2c/IgG1 a | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MVA-S / MVA-S / SARS-CoV-2 | — / MVA-S / SARS-CoV-2 | MVA-S / MVA-S | ||||||||||||||||
| (K18-hACE2 mice) | (K18-hACE2 mice) | (C57BL/6 mice) | ||||||||||||||||
| S | RBD | S | RBD | S | RBD | |||||||||||||
| IgG1 | IgG2c | IgG2c/IgG1 | IgG1 | IgG2c | IgG2c/IgG1 | IgG1 | IgG2c | IgG2c/IgG1 | IgG1 | IgG2c | IgG2c/IgG1 | IgG1 | IgG2c | IgG2c/IgG1 | IgG1 | IgG2c | IgG2c/IgG1 | |
| 10 days post-boost (prechallenge) | 24.414 | 152.587 | 6,25 | 1.562 | 61.035 | 39,07 | 1.562 | 9.765 | 6,25 | 625 | 3.906 | 6,25 | – | – | – | – | – | – |
| Day 4 postchallenge | 24.414 | 152.587 | 6,25 | 438 | 61.035 | 139,51 | 1.562 | 9.765 | 6,25 | 100 | 3.906 | 39,06 | – | – | – | – | – | – |
| Day 15 postchallenge | 24.414 | 152.587 | 6,25 | 1.562 | 61.035 | 39,07 | 152.587 | 953.674 | 6,25 | 9.765 | 152.587 | 15,63 | – | – | – | – | – | – |
| Day 6 post-rechallenge | 24.414 | 152.587 | 6,25 | 625 | 42.724 | 69,36 | 61.035 | 953.674 | 15,63 | 2.734 | 152.587 | 55,81 | – | – | – | – | – | – |
| 6 months post-boost | – | – | – | – | – | – | – | – | – | – | – | – | 3.906 | 17.089 | 4,38 | 625 | 9.765 | 15,62 |
aMean titers of IgG2c and IgG1 isotype antibodies against S and RBD proteins from duplicates of pooled sera samples obtained from the different immunization regimens studied are represented, including the ratio IgG2c/IgG1. –: not applicable.